Kato Katz and PCR database 12 months collection. by Jannet A. Tobon Ramos (20855642)

“…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”

Master database baseline, 4 weeks and 1 year. by Jannet A. Tobon Ramos (20855642)

“…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”

Table 1_Elevated CO2 decreases micronutrient Zn but not Fe in vegetables – evidence from a meta-analysis.docx by Xiaolin Wang (303612)

Table 1_Fertilization decreases the effect of ammonium nitrogen on microorganisms in Chinese Carex tibetikobresia meadows during rest-grazing.docx by Xuanbo Zhou (19374205)

Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”

Data Sheet 1_A synonymous mutation of rs1137070 cause the mice Maoa gene transcription and translation to decrease.pdf by Kai Xin Li (19696741)

Data Sheet 1_Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.pdf by Jingjing Fang (124938)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Ischemic heart disease-related mortality trends in older adult population and stratified for census regions in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in mainland China and their temporal trends. by Yu Fu (16582)

Subjects:

Projections of incidence for hematological malignancies in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for metropolitan vs. non-metropolitan in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Age- and sex-specific distribution of prevalence, incidence, mortality, and DALY rates for lymphoma, multiple myeloma, and other hematological neoplasms in mainland China. by Yu Fu (16582)

Subjects:

Disease burden trends of leukemia and lymphoma analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for gender in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Disease burden trends of multiple myeloma and other hematological neoplasms analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for older vs. young population in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in Taiwan and their temporal trends. by Yu Fu (16582)

Subjects: